Patent Application
20220002680
The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Nov. 6, 2019, is named 043214-089130WOPT_SL.txt and is 210,810 bytes in size.
The present invention is directed compositions and methods of treating cancer using regulatable fusogenic oncolytic herpes simplex virus 1 (HSV-1) virus.
Oncolytic viral therapy entails harnessing the ability of a virus to reproduce in and lyse human cells and directing this viral replication-dependent lysis preferentially toward cancerous cells. Advances in cancer biology, together with a detailed understanding of the roles of host factors and virus-encoded gene products in controlling virus production in infected cells, have facilitated the use of some viruses as potential therapeutic agents against cancer (Aghi and Martuza, 2005; Parato et al., 2005). Herpes simplex virus (HSV) possesses several unique properties as an oncolytic agent (Aghi and Martuza, 2005). It can infect a broad range of cell types, leading to the replication of new virus and cell death. HSV has a short replication cycle (9 to 18 h) and encodes many non-essential genes that, when deleted, greatly restrict the ability of the virus to replicate in non-dividing normal cells. Because of its large genome, multiple therapeutic genes can be packaged into the genome of oncolytic recombinants.
The use of a replication-conditional strain of HSV-1 as an oncolytic agent was first reported for the treatment of malignant gliomas (Martuza et al., 1991). Since then, various efforts have been made in an attempt to broaden their therapeutic efficacy and increase the replication specificity of the virus in tumor cells. Not surprisingly, however, deletion of genes that impair viral replication in normal cells also leads to a marked decrease in the oncolytic activity of the virus for the targeted tumor cells (Advani et al., 1998; Chung et al., 1999). Currently, no oncolytic viruses that are able to kill only tumor cells while leaving normal cells intact are available. Consequently, the therapeutic doses of existing oncolytic viruses are significantly restricted (Aghi and Martuza, 2005). The availability of an oncolytic virus whose replication can be tightly controlled and adjusted pharmacologically would offer greatly increased safety and therapeutic efficacy. Such a regulatable oncolytic virus would minimize unwanted replication in adjacent and distant tissues as well as undesirable progeny virus overload in the target area after the tumor has been eliminated. This regulatory feature would also allow the oncolytic activity of the virus to be quickly shut down should adverse effects be detected (Aghi and Martuza, 2005; Shen and Nemunaitis, 2005). Work described herein presents a regulatable fusogenic variant of a oncolytic HSV that is significantly more effective at killing cancer cells than its non-fusogenic parent.
The invention described herein is based, in part, on an isolated fusogenic variant of a novel oncolytic HSV-1 recombinant, KTR27, whose replication can be tightly controlled and regulated by tetracycline in a dose-dependent manner (Yao et al., J Virol, 2010) (U.S. Pat. No. 8,236,941). Work described herein demonstrates that this fusogenic variant, KTR27-F, is significantly more superior to its non-fusogenic parent in lysing various tested human cancer cells. Like KTR27, replication of KTR27-F in primary human fibroblasts is markedly reduced compared with various human tumor cells. The yield of KTR27-F in human breast cancer cells (MCF-7) is 21,800-fold higher than in growth-arrested normal human breast fibroblasts. Moreover, while infection of growth-arrested human breast fibroblasts with KTR27 induced little or no cytotoxicity in the infected cells, over 99% of infected MCF7 cells were non-viable compared with the mock-infected control. Collectively, KTR27-F represents proof-of-concept advancement in the design of safer and more effective oncolytic viruses.
Accordingly, one aspect described herein provides an oncolytic Herpes Simplex Virus (HSV) comprising recombinant DNA, wherein the recombinant DNA has both ICP0 and ICP34.5 gene deleted or does not express functional ICP0 and ICP34.5
Another aspect described herein provides an oncolytic Herpes Simplex Virus (HSV) comprising recombinant DNA, wherein the recombinant DNA comprises: a gene comprising a 5′ untranslated region and a HSV-1, or HSV-2, ICP27 gene that is operably linked to an ICP27 promoter comprising a TATA element; a tetracycline operator sequence positioned between 6 and 24 nucleotides 3′ to said TATA element, wherein the ICP27 gene lies 3′ to said tetracycline operator sequence; a ribozyme sequence located in said 5′ untranslated region of said gene; a gene sequence encoding tetracycline repressor operably linked to an immediate-early promoter, wherein the gene sequence is located at the ICP0 locus; and a variant gene that increases syncytium formation as compared to wild type, wherein the HSV-1, or HSV-2, variant gene is selected from the group consisting of: a glycoprotein K (gK) variant; a glycoprotein B (gB) variant; a UL24 variant; and UL20 gene variant, wherein said oncolytic HSV does not encode functional ICP0 and functional ICP34.5 protein.
In one embodiment of any aspect, the variant gene is a gK variant gene that encodes an amino acid substitution selected from the group consisting of: an Ala to Val amino acid substitution corresponding to amino acid 40 of SEQ ID NO: 2; an Ala to “x” amino acid substitution corresponding to amino acid 40 of SEQ ID NO: 2, wherein “x” is any amino acid; an Asp to Asn amino acid substitution corresponding to amino acid 99 of SEQ ID NO: 2; a Leu to Pro amino acid substitution corresponding to amino acid 304 of SEQ ID NO: 2; and an Arg to Leu amino acid substitution corresponding to amino acid 310 of SEQ ID NO: 2. In one embodiment, the oncolytic HSV further comprises a variant UL24 gene that encodes a Ser to Asn amino acid substitution corresponding to amino acid 113 of SEQ ID NO: 3. In one embodiment of any aspect, the variant gene is a UL24 gene that encodes a Ser to Asn amino acid substitution corresponding to amino acid 113 of SEQ ID NO: 3. In one embodiment, the amino acids described herein can be substituted for any known amino acid.
In one embodiment of any aspect, the tetracycline operator sequence comprises two Op2 repressor binding sites.
In one embodiment of any aspect, the ICP27 promoter is an HSV-1 or HSV-2 ICP27 promoter.
In one embodiment of any aspect, the immediate-early promoter is an HSV-1 or HSV-2 immediate-early promoter or the HCMV immediate-early promoter.
In one embodiment of any aspect, the HSV immediate-early promoter is selected from the group consisting of: ICP0 promoter, ICP4 promoter, ICP27 promoter, and ICP22 promoter.
In one embodiment of any aspect, the recombinant DNA is part of the HSV-1 genome. In one embodiment of any aspect, the recombinant DNA is part of the HSV-2 genome.
In one embodiment of any aspect, the oncolytic HSV described herein further comprises a pharmaceutically acceptable carrier
In one embodiment of any aspect, the oncolytic HSV described herein further encodes at least one polypeptide that can increase the efficacy of the oncolytic HSV to induce an anti-tumor-specific immunity. In one embodiment, the at least one polypeptide encodes a product selected from the group consisting of: interleukin 2 (IL2), interleukin 12 (IL12), interleukin 15 (IL15), an anti-PD-1 antibody or antibody reagent, an anti-PD-L1 antibody or antibody reagent, an anti-OX40 antibody or antibody reagent, CTLA-4 antibody or antibody reagent, TIM-3 antibody or antibody reagent, and TIGIT antibody or antibody reagent.
Another aspect described herein provides a composition comprising any of the oncolytic HSV described herein. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier.
Another aspect described herein provides a method for treating cancer comprising administering any of the oncolytic HSV described herein or a composition thereof to a subject having cancer.
In one embodiment of any aspect, the cancer is a solid tumor.
In one embodiment of any aspect, the tumor is benign or malignant.
In one embodiment of any aspect, the subject is diagnosed or has been diagnosed as having a carcinoma, a melanoma, a sarcoma, a germ cell tumor, or a blastoma. In one embodiment of any aspect, the subject is diagnosed or has been diagnosed as having non-small-cell lung cancer, breast cancer, brain cancer, colon cancer, prostate cancer, liver cancer, lung cancer, ovarian cancer, skin cancer, and pancreatic cancer.
In one embodiment of any aspect, the cancer is metastatic.
In one embodiment of aspect, the oncolytic HSV is administered directly to the tumor.
In one embodiment of any aspect, the method further comprises administering an agent that regulates the tet operator. In one embodiment, the agent is doxycycline or tetracycline. In one embodiment, the agent is administered locally or systemically.
All references cited herein are incorporated by reference in their entirety as though fully set forth.
Unless otherwise defined herein, scientific and technical terms used in connection with the present application shall have the meanings that are commonly understood by those of ordinary skill in the art to which this disclosure belongs. It should be understood that this invention is not limited to the particular methodology, protocols, and reagents, etc., described herein and as such can vary. Definitions of common terms can be found in Singleton et al., Dictionary of Microbiology and Molecular Biology 3rd ed., J. Wiley & Sons New York, N.Y. (2001); March, Advanced Organic Chemistry Reactions, Mechanisms and Structure 5th ed., J. Wiley & Sons New York, N.Y. (2001); Michael Richard Green and Joseph Sambrook, Molecular Cloning: A Laboratory Manual, 4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., USA (2012); Davis et al., Basic Methods in Molecular Biology, Elsevier Science Publishing, Inc., New York, USA (2012); Jon Lorsch (ed.) Laboratory Methods in Enzymology: DNA, Elsevier, (2013); Frederick M. Ausubel (ed.), Current Protocols in Molecular Biology (CPMB), John Wiley and Sons, (2014); John E. Coligan (ed.), Current Protocols in Protein Science (CPPS), John Wiley and Sons, Inc., (2005); and Ethan M Shevach, Warren Strobe, (eds.) Current Protocols in Immunology (CPI) (John E. Coligan, ADA M Kruisbeek, David H Margulies, John Wiley and Sons, Inc., (2003); each of which provide one skilled in the art with a general guide to many of the terms used in the present application.
As used herein, a “subject” means a human or animal. Usually the animal is a vertebrate such as a primate, rodent, domestic animal or game animal. Primates include, for example, chimpanzees, cynomologous monkeys, spider monkeys, and macaques, e.g., Rhesus. Rodents include, for example, mice, rats, woodchucks, ferrets, rabbits and hamsters. Domestic and game animals include, for example, cows, horses, pigs, deer, bison, buffalo, feline species, e.g., domestic cat, canine species, e.g., dog, fox, wolf, avian species, e.g., chicken, emu, ostrich, and fish, e.g., trout, catfish and salmon. In some embodiments, the subject is a mammal, e.g., a primate, e.g., a human. The terms, “individual,” “patient” and “subject” are used interchangeably herein.
Preferably, the subject is a mammal. The mammal can be a human, non-human primate, mouse, rat, dog, cat, horse, or cow, but is not limited to these examples. Mammals other than humans can be advantageously used as subjects that represent animal models of disease e.g., cancer. A subject can be male or female.
A subject can be one who has been previously diagnosed with or identified as suffering from or having a condition in need of treatment (e.g. cancer) or one or more complications related to such a condition, and optionally, have already undergone treatment for the condition or the one or more complications related to the condition. Alternatively, a subject can also be one who has not been previously diagnosed as having such condition or related complications. For example, a subject can be one who exhibits one or more risk factors for the condition or one or more complications related to the condition or a subject who does not exhibit risk factors.
As used herein, the terms “treat,” “treatment,” “treating,” or “amelioration” refer to therapeutic treatments, wherein the object is to reverse, alleviate, ameliorate, inhibit, slow down or stop the progression or severity of a condition associated with a disease or disorder, e.g. cancer. The term “treating” includes reducing or alleviating at least one adverse effect or symptom of a condition, disease or disorder. Treatment is generally “effective” if one or more symptoms or clinical markers are reduced. Alternatively, treatment is “effective” if the progression of a disease is reduced or halted. That is, “treatment” includes not just the improvement of symptoms or markers, but also a cessation of, or at least slowing of, progress or worsening of symptoms compared to what would be expected in the absence of treatment. Beneficial or desired clinical results include, but are not limited to, alleviation of one or more symptom(s), diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, remission (whether partial or total), and/or decreased mortality, whether detectable or undetectable. The term “treatment” of a disease also includes providing relief from the symptoms or side-effects of the disease (including palliative treatment).
In the various embodiments described herein, it is further contemplated that variants (naturally occurring or otherwise), alleles, homologs, conservatively modified variants, and/or conservative substitution variants of any of the particular polypeptides described are encompassed. As to amino acid sequences, one of ordinary skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters a single amino acid or a small percentage of amino acids in the encoded sequence is a “conservatively modified variant” where the alteration results in the substitution of an amino acid with a chemically similar amino acid and retains the desired activity of the polypeptide. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles consistent with the disclosure.
A given amino acid can be replaced by a residue having similar physiochemical characteristics, e.g., substituting one aliphatic residue for another (such as Ile, Val, Leu, or Ala for one another), or substitution of one polar residue for another (such as between Lys and Arg; Glu and Asp; or Gln and Asn). Other such conservative substitutions, e.g., substitutions of entire regions having similar hydrophobicity characteristics, are well known. Polypeptides comprising conservative amino acid substitutions can be tested in any one of the assays described herein to confirm that a desired activity, e.g. ligan-mediated receptor activity and specificity of a native or reference polypeptide is retained.
Amino acids can be grouped according to similarities in the properties of their side chains (in A. L. Lehninger, in Biochemistry, second ed., pp. 73-75, Worth Publishers, New York (1975)): (1) non-polar: Ala (A), Val (V), Leu (L), Ile (I), Pro (P), Phe (F), Trp (W), Met (M); (2) uncharged polar: Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gln (Q); (3) acidic: Asp (D), Glu (E); (4) basic: Lys (K), Arg (R), His (H). Alternatively, naturally occurring residues can be divided into groups based on common side-chain properties: (1) hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile; (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; (3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues that influence chain orientation: Gly, Pro; (6) aromatic: Trp, Tyr, Phe. Non-conservative substitutions will entail exchanging a member of one of these classes for another class. Particular conservative substitutions include, for example; Ala into Gly or into Ser; Arg into Lys; Asn into Gln or into His; Asp into Glu; Cys into Ser; Gln into Asn; Glu into Asp; Gly into Ala or into Pro; His into Asn or into Gln; Ile into Leu or into Val; Leu into Ile or into Val; Lys into Arg, into Gln or into Glu; Met into Leu, into Tyr or into Ile; Phe into Met, into Leu or into Tyr; Ser into Thr; Thr into Ser; Trp into Tyr; Tyr into Trp; and/or Phe into Val, into Ile or into Leu.
In some embodiments, a polypeptide described herein (or a nucleic acid encoding such a polypeptide) can be a functional fragment of one of the amino acid sequences described herein. As used herein, a “functional fragment” is a fragment or segment of a peptide which retains at least 50% of the wildtype reference polypeptide's activity according to an assay known in the art or described below herein. A functional fragment can comprise conservative substitutions of the sequences disclosed herein.
In some embodiments, a polypeptide described herein can be a variant of a polypeptide or molecule as described herein. In some embodiments, the variant is a conservatively modified variant. Conservative substitution variants can be obtained by mutations of native nucleotide sequences, for example. A “variant,” as referred to herein, is a polypeptide substantially homologous to a native or reference polypeptide, but which has an amino acid sequence different from that of the native or reference polypeptide because of one or a plurality of deletions, insertions or substitutions. Variant polypeptide-encoding DNA sequences encompass sequences that comprise one or more additions, deletions, or substitutions of nucleotides when compared to a native or reference DNA sequence, but that encode a variant protein or fragment thereof that retains activity of the non-variant polypeptide. A wide variety of PCR-based site-specific mutagenesis approaches are known in the art and can be applied by the ordinarily skilled artisan.
A variant amino acid or DNA sequence can be at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more, identical to a native or reference sequence. The degree of homology (percent identity) between a native and a mutant sequence can be determined, for example, by comparing the two sequences using freely available computer programs commonly employed for this purpose on the world wide web (e.g. BLASTp or BLASTn with default settings).
Alterations of the native amino acid sequence can be accomplished by any of a number of techniques known to one of skill in the art. Mutations can be introduced, for example, at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites permitting ligation to fragments of the native sequence. Following ligation, the resulting reconstructed sequence encodes an analog having the desired amino acid insertion, substitution, or deletion. Alternatively, oligonucleotide-directed site-specific mutagenesis procedures can be employed to provide an altered nucleotide sequence having particular codons altered according to the substitution, deletion, or insertion required. Techniques for making such alterations are well established and include, for example, those disclosed by Walder et al. (Gene 42:133, 1986); Bauer et al. (Gene 37:73, 1985); Craik (BioTechniques, January 1985, 12-19); Smith et al. (Genetic Engineering: Principles and Methods, Plenum Press, 1981); and U.S. Pat. Nos. 4,518,584 and 4,737,462, which are herein incorporated by reference in their entireties. Any cysteine residue not involved in maintaining the proper conformation of a polypeptide also can be substituted, generally with serine, to improve the oxidative stability of the molecule and prevent aberrant crosslinking. Conversely, cysteine bond(s) can be added to a polypeptide to improve its stability or facilitate oligomerization.
As used herein, the term “DNA” is defined as deoxyribonucleic acid. The term “polynucleotide” is used herein interchangeably with “nucleic acid” to indicate a polymer of nucleosides. Typically, a polynucleotide is composed of nucleosides that are naturally found in DNA or RNA (e.g., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine) joined by phosphodiester bonds. However, the term encompasses molecules comprising nucleosides or nucleoside analogs containing chemically or biologically modified bases, modified backbones, etc., whether or not found in naturally occurring nucleic acids, and such molecules may be preferred for certain applications. Where this application refers to a polynucleotide it is understood that both DNA, RNA, and in each case both single- and double-stranded forms (and complements of each single-stranded molecule) are provided. “Polynucleotide sequence” as used herein can refer to the polynucleotide material itself and/or to the sequence information (i.e. the succession of letters used as abbreviations for bases) that biochemically characterizes a specific nucleic acid. A polynucleotide sequence presented herein is presented in a 5′ to 3′ direction unless otherwise indicated.
The term “operably linked,” as used herein, refers to the arrangement of various nucleic acid molecule elements relative to each other such that the elements are functionally connected and are able to interact with each other. Such elements may include, without limitation, a promoter, an enhancer, a polyadenylation sequence, one or more introns and/or exons, and a coding sequence of a gene of interest to be expressed. The nucleic acid sequence elements, when operably linked, can act together to modulate the activity of one another, and ultimately may affect the level of expression of the gene of interest, including any of those encoded by the sequences described above.
The term “vector,” as used herein, refers to a carrier nucleic acid molecule into which a nucleic acid sequence can be inserted for introduction into a cell where it can be replicated. A nucleic acid sequence can be “exogenous,” which means that it is foreign to the cell into which the vector is being introduced or that the sequence is homologous to a sequence in the cell but in a position within the host cell nucleic acid in which the sequence is ordinarily not found. Vectors include plasmids, cosmids, viruses (bacteriophage, animal viruses, and plant viruses), and artificial chromosomes (e.g., YACs). One of skill in the art would be well equipped to construct a vector through standard recombinant techniques (see, for example, Maniatis et al., 1988 and Ausubel et al., 1994, both of which are incorporated herein by reference). Additionally, the techniques described herein and demonstrated in the referenced figures are also instructive with regard to effective vector construction.
The term “oncolytic HSV-1 vector” refers to a genetically engineered HSV-1 virus corresponding to at least a portion of the genome of HSV-1 that is capable of infecting a target cell, replicating, and being packaged into HSV-1 virions. The genetically engineered virus comprises deletions and or mutations and or insertions of nucleic acid that render the virus oncolytic such that the engineered virus replicates in- and kills-tumor cells by oncolytic activity. The virus may be attenuated or non-attenuated. The virus may or may not deliver a transgene—that differs from the HSV viral genome. In one embodiment, the oncolytic HSV-1 vector does not express a transgene to produce a protein foreign to the virus.
The term “promoter,” as used herein, refers to a nucleic acid sequence that regulates, either directly or indirectly, the transcription of a corresponding nucleic acid coding sequence to which it is operably linked. The promoter may function alone to regulate transcription, or, in some cases, may act in concert with one or more other regulatory sequences such as an enhancer or silencer to regulate transcription of the gene of interest. The promoter comprises a DNA regulatory sequence, wherein the regulatory sequence is derived from a gene, which is capable of binding RNA polymerase and initiating transcription of a downstream (3′-direction) coding sequence. A promoter generally comprises a sequence that functions to position the start site for RNA synthesis. The best-known example of this is the TATA box, but in some promoters lacking a TATA box, such as, for example, the promoter for the mammalian terminal deoxynucleotidyl transferase gene and the promoter for the SV40 late genes, a discrete element overlying the start site itself helps to fix the place of initiation. Additional promoter elements regulate the frequency of transcriptional initiation. Typically, these are located in the region 30-110 bp upstream of the start site, although a number of promoters have been shown to contain functional elements downstream of the start site as well. To bring a coding sequence “under the control of” a promoter, one can position the 5′ end of the transcription initiation site of the transcriptional reading frame “downstream” of (i.e., 3′ of) the chosen promoter. The “upstream” promoter stimulates transcription of the DNA and promotes expression of the encoded RNA.
The spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another. Depending on the promoter used, individual elements can function either cooperatively or independently to activate transcription. The promoters described herein may or may not be used in conjunction with an “enhancer,” which refers to a cis-acting regulatory sequence involved in the transcriptional activation of a nucleic acid sequence, such as those for the genes, or portions or functional equivalents thereof, listed herein.
A promoter may be one naturally associated with a nucleic acid sequence, as may be obtained by isolating the 5′ non-coding sequences located upstream of the coding segment and/or exon. Such a promoter can be referred to as “endogenous.” Similarly, an enhancer may be one naturally associated with a nucleic acid sequence, located either downstream or upstream of that sequence. Alternatively, certain advantages may be gained by positioning the coding nucleic acid segment under the control of a recombinant or heterologous promoter, which refers to a promoter that is not normally associated with a nucleic acid sequence in its natural environment. A recombinant or heterologous enhancer refers also to an enhancer not normally associated with a nucleic acid sequence in its natural environment. Such promoters or enhancers may include promoters or enhancers of other genes, and promoters or enhancers isolated from any other virus, or prokaryotic or eukaryotic cell, and promoters or enhancers not “naturally occurring,” i.e., containing different elements of different transcriptional regulatory regions, and/or mutations that alter expression. For example, promoters that are most commonly used in recombinant DNA construction include, the HCMV immediate-early promoter, the beta-lactamase (penicillinase), lactose and tryptophan (trp) promoter systems.
A “gene,” or a “sequence which encodes” a particular protein, is a nucleic acid molecule which is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide in vitro or in vivo when placed under the control of one or more appropriate regulatory sequences. A gene of interest can include, but is no way limited to, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic DNA, and even synthetic DNA sequences. A transcription termination sequence will usually be located 3′ to the gene sequence. Typically, a polyadenylation signal is provided to terminate transcription of genes inserted into a recombinant virus.
The term “polypeptide” as used herein refers to a polymer of amino acids. The terms “protein” and “polypeptide” are used interchangeably herein. A peptide is a relatively short polypeptide, typically between about 2 and 60 amino acids in length. Polypeptides used herein typically contain amino acids such as the 20 L-amino acids that are most commonly found in proteins. However, other amino acids and/or amino acid analogs known in the art can be used. One or more of the amino acids in a polypeptide may be modified, for example, by the addition of a chemical entity such as a carbohydrate group, a phosphate group, a fatty acid group, a linker for conjugation, functionalization, etc. A polypeptide that has a nonpolypeptide moiety covalently or noncovalently associated therewith is still considered a “polypeptide.” Exemplary modifications include glycosylation and palmitoylation. Polypeptides can be purified from natural sources, produced using recombinant DNA technology or synthesized through chemical means such as conventional solid phase peptide synthesis, etc. The term “polypeptide sequence” or “amino acid sequence” as used herein can refer to the polypeptide material itself and/or to the sequence information (i.e., the succession of letters or three letter codes used as abbreviations for amino acid names) that biochemically characterizes a polypeptide. A polypeptide sequence presented herein is presented in an N-terminal to C-terminal direction unless otherwise indicated.
The term “transgene” refers to a particular nucleic acid sequence encoding a polypeptide or a portion of a polypeptide to be expressed in a cell into which the nucleic acid sequence is inserted. The term “transgene” is meant to include (1) a nucleic acid sequence that is not naturally found in the cell (i.e., a heterologous nucleic acid sequence); (2) a nucleic acid sequence that is a mutant form of a nucleic acid sequence naturally found in the cell into which it has been inserted; (3) a nucleic acid sequence that serves to add additional copies of the same (i.e., homologous) or a similar nucleic acid sequence naturally occurring in the cell into which it has been inserted; or (4) a silent naturally occurring or homologous nucleic acid sequence whose expression is induced in the cell into which it has been inserted. A “mutant form” or “modified nucleic acid” or “modified nucleotide” sequence means a sequence that contains one or more nucleotides that are different from the wild-type or naturally occurring sequence, i.e., the mutant nucleic acid sequence contains one or more nucleotide substitutions, deletions, and/or insertions. In some cases, the gene of interest may also include a sequence encoding a leader peptide or signal sequence such that the transgene product may be secreted from the cell.
As used herein, the term “antibody reagent” refers to a polypeptide that includes at least one immunoglobulin variable domain or immunoglobulin variable domain sequence and which specifically binds a given antigen. An antibody reagent can comprise an antibody or a polypeptide comprising an antigen-binding domain of an antibody. In some embodiments of any of the aspects, an antibody reagent can comprise a monoclonal antibody or a polypeptide comprising an antigen-binding domain of a monoclonal antibody. For example, an antibody can include a heavy (H) chain variable region (abbreviated herein as VH), and a light (L) chain variable region (abbreviated herein as VL). In another example, an antibody includes two heavy (H) chain variable regions and two light (L) chain variable regions. The term “antibody reagent” encompasses antigen-binding fragments of antibodies (e.g., single chain antibodies, Fab and sFab fragments, F(ab′)2, Fd fragments, Fv fragments, scFv, CDRs, and domain antibody (dAb) fragments (see, e.g. de Wildt et al., Eur J. Immunol. 1996; 26(3):629-39; which is incorporated by reference herein in its entirety)) as well as complete antibodies. An antibody can have the structural features of IgA, IgG, IgE, IgD, or IgM (as well as subtypes and combinations thereof). Antibodies can be from any source, including mouse, rabbit, pig, rat, and primate (human and non-human primate) and primatized antibodies. Antibodies also include midibodies, nanobodies, humanized antibodies, chimeric antibodies, and the like.
The term “oncolytic activity,” as used herein, refers to cytotoxic effects in vitro and/or in vivo exerted on tumor cells without any appreciable or significant deleterious effects to normal cells under the same conditions. The cytotoxic effects under in vitro conditions are detected by various means as known in prior art, for example, by staining with a selective stain for dead cells, by inhibition of DNA synthesis, or by apoptosis. Detection of the cytotoxic effects under in vivo conditions is performed by methods known in the art.
A “biologically active” portion of a molecule, as used herein, refers to a portion of a larger molecule that can perform a similar function as the larger molecule. Merely by way of non-limiting example, a biologically active portion of a promoter is any portion of a promoter that retains the ability to influence gene expression, even if only slightly. Similarly, a biologically active portion of a protein is any portion of a protein which retains the ability to perform one or more biological functions of the full-length protein (e.g. binding with another molecule, phosphorylation, etc.), even if only slightly.
As used herein, the term “administering,” refers to the placement of a therapeutic or pharmaceutical composition as disclosed herein into a subject by a method or route which results in at least partial delivery of the agent at a desired site. Pharmaceutical compositions comprising agents as disclosed herein can be administered by any appropriate route which results in an effective treatment in the subject.
The term “statistically significant” or “significantly” refers to statistical significance and generally means a two standard deviation (2SD) or greater difference.
Other than in the operating examples, or where otherwise indicated, all numbers expressing quantities of ingredients or reaction conditions used herein should be understood as modified in all instances by the term “about.” The term “about” when used in connection with percentages can mean ±1%.
As used herein, the term “comprising” means that other elements can also be present in addition to the defined elements presented. The use of “comprising” indicates inclusion rather than limitation. The term “consisting of” refers to compositions, methods, and respective components thereof as described herein, which are exclusive of any element not recited in that description of the embodiment. As used herein the term “consisting essentially of” refers to those elements required for a given embodiment. The term permits the presence of additional elements that do not materially affect the basic and novel or functional characteristic(s) of that embodiment of the technology.
The singular terms “a,” “an,” and “the” include plural referents unless context clearly indicates otherwise. Similarly, the word “or” is intended to include “and” unless the context clearly indicates otherwise. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of this disclosure, suitable methods and materials are described below. The abbreviation, “e.g.” is derived from the Latin exempli gratia, and is used herein to indicate a non-limiting example. Thus, the abbreviation “e.g.” is synonymous with the term “for example.”
In some embodiments, the numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth, used to describe and claim certain embodiments of the application are to be understood as being modified in some instances by the term “about.” Accordingly, in some embodiments, the numerical parameters set forth in the written description and attached claims are approximations that can vary depending upon the desired properties sought to be obtained by a particular embodiment. In some embodiments, the numerical parameters should be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of some embodiments of the application are approximations, the numerical values set forth in the specific examples are reported as precisely as practicable.
With the aforementioned preliminary descriptions and definitions in mind, additional background is provided herein below to provide context for the genesis and development of the inventive vectors, compositions and methods described herein.
Exemplary embodiments are illustrated in the referenced figures. It is intended that the embodiments and figures disclosed herein are to be considered illustrative rather than restrictive.
Oncolytic viruses are genetically modified viruses that preferentially replicate in host cancer cells, leading to the production of new viruses, lysis of cancer cells, and ultimately, induction of tumor-specific immunity. Using the T-REx™ (Invitrogen, CA) gene switch technology and a self-cleaving ribozyme, a novel oncolytic HSV-1 recombinant, KTR27, was constructed, whose replication can be tightly controlled and regulated by tetracycline in a dose-dependent manner. This virus is further described in Yao et al., J Virol, 2010 and U.S. Pat. No. 8,236,941, which are incorporated herein by reference in their entirety. Infection of normal replicating cells as well as multiple human cancer cell types with KTR27 in the presence of tetracycline led to 1000- to 250,000-fold higher progeny virus production than in the absence of tetracycline, while little viral replication and virus-associated cytotoxicity are observed in infected growth-arrested normal human cells. Importantly, KTR27 is very effective against pre-established Non-Small cell lung cancer in nude mice and can prevent the growth of pre-established M3 mouse melanoma in immuno-competent mice. Intratumoral inoculation of KTR27 can elicit systemic immune response that can effectively prevent the growth of a distant tumor in immuno-competent mice.
In an effort to further enhance the therapeutic efficacy of KTR27 and its effectiveness in eliciting tumor specific immunity following oncolytic virotherapy, a fusogenic variant of KTR27, KTR27-F, was isolated. Work described herein demonstrate that KTR27-F is significantly more superior to its non-fusogenic parent in lysing various tested human cancer cells. Like KTR27, replication of KTR27-F in primary human fibroblasts is markedly reduced compared with various human tumor cells. The yield of KTR27-F in human breast cancer cells (MCF-7) is 21,800-fold higher than in growth-arrested normal human breast fibroblasts. Moreover, while infection of growth-arrested human breast fibroblasts with KTR27-F induced little or no cytotoxicity in the infected cells, over 99% of infected MCF7 cells were non-viable compared with the mock-infected control. Collectively, KTR27-F represents an advancement in the design of safer and more effective oncolytic viruses.
HSV-1 is a human neurotropic virus that is capable of infecting virtually all vertebrate cells. Natural infections follow either a lytic, replicative cycle or establish latency, usually in peripheral ganglia, where the DNA is maintained indefinitely in an episomal state. HSV-1 contains a double-stranded, linear DNA genome, about 152 kilobases in length, which has been completely sequenced by McGeoch (McGeoch et al., J. Gen. Virol. 69: 1531 (1988); McGeoch et al., Nucleic Acids Res 14: 1727 (1986); McGeoch et al., J. Mol. Biol. 181: 1 (1985); Perry and McGeoch, J. Gen. Virol. 69:2831 (1988); Szpara M L et al., J Virol. 2010, 84:5303; Macdonald S J et al., J Virol. 2012, 86:6371). DNA replication and virion assembly occurs in the nucleus of infected cells. Late in infection, concatemeric viral DNA is cleaved into genome length molecules which are packaged into virions. In the CNS, herpes simplex virus spreads transneuronally followed by intraaxonal transport to the nucleus, either retrograde or anterograde, where replication occurs.
One aspect described herein provides an oncolytic Herpes Simplex Virus (HSV) comprising recombinant DNA, wherein the recombinant DNA has both ICP0 and ICP34.5 gene product deleted or does not express functional ICP0 and ICP34.5.
Infected cell protein 34.5 (ICP34.5) is a protein (e.g., a gene product) expressed by the γ34.5 gene in viruses, such as the herpes simplex virus. IPC34.5 has been shown to block the cellar stress response to a viral infection (Agarwalla, P. K., et al. Method in Mol. Bio., 2012). Infected cell polypeptide 0 (ICP0) is a protein encoded by the HSV-1 α0 gene. ICP0 is generated during the immediate-early phase of viral gene expression. ICP0 is synthesized and transported to the nucleus of the infected host cell, where it promotes transcription from viral genes, disrupts nuclear and cytoplasmic cellular structures, such as the microtubule network, and alters the expression of host genes.
One skilled in the art can determine if the ICP0 or ICP34.5 gene products have been deleted or if the virus does not express functional forms of these gene products using PCR-based assays to detect the presence of the gene in the viral genome or the expression of the gene products, or using functional assays to assess their function, respectively.
In one embodiment, the gene that encodes these gene products contain a mutation, for example, an inactivating mutation, that inhibits proper expression of the gene product. For example, the gene may encode a mutation in the gene product that inhibits proper folding, expression, function, ect. of the gene product. As used herein, the term “inactivating mutation” is intended to broadly mean a mutation or alteration to a gene wherein the expression of that gene is significantly decreased, or wherein the gene product is rendered nonfunctional, or its ability to function is significantly decreased. The term “gene” encompasses both the regions coding the gene product as well as regulatory regions for that gene, such as a promoter or enhancer, unless otherwise indicated.
Ways to achieve such alterations include: (a) any method to disrupt the expression of the product of the gene or (b) any method to render the expressed gene nonfunctional. Numerous methods to disrupt the expression of a gene are known, including the alterations of the coding region of the gene, or its promoter sequence, by insertions, deletions and/or base changes. (See, Roizman, B. and Jenkins, F. J., Science 229: 1208-1214 (1985)).
Further described herein is an oncolytic Herpes Simplex Virus (HSV) comprising recombinant DNA, wherein the recombinant DNA comprises: (a) a gene comprising a 5′ untranslated region and a HSV-1, or HSV-2, ICP27 gene that is operably linked to an ICP27 promoter comprising a TATA element; (b) a tetracycline operator sequence positioned between 6 and 24 nucleotides 3′ to said TATA element, wherein the ICP27 gene lies 3′ to said tetracycline operator sequence; (c) a ribozyme sequence located in said 5′ untranslated region of said gene; (d) a gene sequence encoding tetracycline repressor operably linked to an immediate early promoter, wherein the gene sequence is located at the ICP0 locus; and (e) a variant gene that increases syncytium formation as compared to wild type, wherein the HSV-1, or HSV-2, variant gene is selected from the group consisting of: a glycoprotein K (gK) variant; a glycoprotein B (gB) variant; a UL24 variant; and UL20 gene variant, wherein said oncolytic HSV does not encode functional ICP0 and functional ICP34.5 protein. In one embodiment, the recombinant DNA is derived from the HSV-1 genome. In an alternative embodiment, the recombinant DNA is derived from the HSV-2 genome. In one embodiment, the genome of the HSV comprising recombinant DNA consists of, consists essentially of, or comprises the sequence of SEQ ID NO: 1. The nucleotide sequence of SEQ ID NO: 1 contains the plasmid vector sequence present in pSH-tetR (SEQ ID NO: 9).
An essential feature of the DNA of the present invention is the presence of a gene needed for virus replication that is operably linked to a promoter having a TATA element. A tet operator sequence is located between 6 and 24 nucleotides 3′ to the last nucleotide in the TATA element of the promoter and 5′ to the gene. The strength with which the tet repressor binds to the operator sequence is enhanced by using a form of operator which contains two op2 repressor binding sites (each such site having the nucleotide sequence: TCCCTATCAGTGATAGAGA (SEQ ID NO: 8)) linked by a sequence of 2-20, preferably 1-3 or 10-13, nucleotides. When repressor is bound to this operator, very little or no transcription of the associated gene will occur. If DNA with these characteristics is present in a cell that also expresses the tetracycline repressor, transcription of the gene will be blocked by the repressor binding to the operator and replication of the virus will not occur. However, if tetracycline is introduced, it will bind to the repressor, cause it to dissociate from the operator, and virus replication will proceed.
During productive infection, HSV gene expression falls into three major classes based on the temporal order of expression: immediate-early (a), early (β), and late (γ), with late genes being further divided into two groups, γ1 and γ2. The expression of immediate-early genes does not require de novo viral protein synthesis and is activated by the virion-associated protein VP16 together with cellular transcription factors when the viral DNA enters the nucleus. The protein products of the immediate-early genes are designated infected cell polypeptides ICP0, ICP4, ICP22, ICP27, and ICP47 and it is the promoters of these genes that are preferably used in directing the expression of tet repressor (tetR). The expression of a gene needed for virus replication is under the control of the tetO-containing promoters and these essential genes may be immediate-early, early or late genes, e.g., ICP4, ICP27, ICP8, UL9, gD and VPS. In one embodiment, the tetR has the sequence of SEQ ID NO: 9.
ICP0 plays a major role in enhancing the reactivation of HSV from latency and confers a significant growth advantage on the virus at low multiplicities of infection. ICP4 is the major transcriptional regulatory protein of HSV-1, which activates the expression of viral early and late genes. ICP27 is essential for productive viral infection and is required for efficient viral DNA replication and the optimal expression of subset of viral β genes and γ1 genes as well as viral γ2 genes. The function of ICP4? during HSV infection appears to be to down-regulate the expression of the major histocompatibility complex (MHC) class I on the surface of infected cells.
The recombinant DNA may also include at least one, and preferably at least two, sequences coding for the tetracycline repressor with expression of these sequences being under the control of an immediate early promoter, preferably ICP0 or ICP4. The sequence for the HSV ICP0 and ICP4 promoters and for the genes whose regulation they endogenously control are well known in the art (Perry, et al., J. Gen. Virol. 67:2365-2380 (1986); McGeoch et al., J. Gen. Virol. 72:3057-3075 (1991); McGeoch et al., Nucl. Acid Res. 14:1727-1745 (1986)) and procedures for making viral vectors containing these elements have been previously described (see US published application 2005-02665641n one embodiment, the tetR has the sequence of SEQ ID NO: 9.
These promoters are not only very active in promoting gene expression, they are also specifically induced by VP16, a transactivator released when HSV-1 infects a cell. Thus, transcription from ICP0 promoter is particularly high when repressor is most needed to shut down virus replication. Once appropriate DNA constructs have been produced, they may be incorporated into HSV-1 virus using methods that are well known in the art. One appropriate procedure is described in US 2005-0266564 but other methods known in the art may also be employed.
In various embodiments, the variant gene comprises at least one amino acid change that deviates from the wild-type sequence of the gene. In one embodiment, an oncolytic HSV described herein can contain two or more amino acid substitutions in at least one variant gene. The at least two amino acid substitutions can be found in the same gene, for example, the gK variant gene contains at least two amino acid substitutions. Alternatively, the at least two amino acid substitutions can be found in the at least two different genes, for example, the gK variant gene and the UL24 variant gene each contains at least one amino acid substitutions.
SEQ ID NO: 2 is the amino acid sequence encoding gK (strain KOS).
SEQ ID NO: 3 is the amino acid sequence encoding UL24 (strain KOS).
Exemplary amino acid substitutions present in the variant gene are described in Table 1.
In Table 1, “X” refers to any known amino acid. It is specifically contemplated herein that any amino acid in a variant gene can be substituted for any known amino acid. The list provided in Table 1 is meant to be exemplary, and is in no way supposed to be limiting to the invention. All mutations listed in table 1 for gK are derived from the HSV-1 KOS strain.
The oncolytic HSV described herein comprises a sequence encoding a ribozyme. A ribozyme is an RNA molecule that is capable of catalyzing a biochemical reaction in a similar manner as a protein enzyme. For example, a ribozyme is commonly known to facilitate cleavage or ligation of RNA and DNA, and peptide bond formation. Ribozymes have further roles in RNA processing, such as RNA splicing, viral replication, and transfer RNA biosynthesis. In one embodiment, the oncolytic HSV described herein has a ribozyme sequence that is naturally occurring. In an alternative embodiment, the oncolytic HSV described herein has a synthetic ribozyme sequence, e.g., a non-naturally occurring ribozyme. Ribozymes are further described in, e.g., Yen et al., Nature 431:471-476, 2004, the contents of which are incorporated herein by reference in its entirety. In one embodiment, the ribozyme is N107 ribozyme.
SEQ ID NO: 4 is a nucleotide sequence encoding N107 ribozyme.
In one embodiment, the oncolytic HSV described herein further comprises at least one polypeptide that encodes a product (e.g., a protein, a gene, a gene product, or an antibody or antibody reagent) that can increase the efficacy of the oncolytic HSV to induce an anti-tumor-specific immunity. Exemplary products include, but are not limited to, interleukin 2 (IL2), interleukin 12 (IL12), interleukin 15 (IL15), an anti-PD-1 antibody or antibody reagent, an anti-PD-L1 antibody or antibody reagent, an anti-OX40 antibody or antibody reagent, CTLA-4 antibody or antibody reagent, TIM-3 antibody or antibody reagent, and TIGIT antibody or antibody reagent. In one embodiment, the product is a fragment of IL-2, IL-12, or IL-15, that comprises the same functionality of IL-2, IL-12, or IL-15, as described herein below. One skilled in the art can determine if an anti-tumor specific immunity is induced using stand techniques in the art, which are further described in, for example, Clay, T M, et al. Clinical Cancer Research (2001); Malyguine, A, et al. J Transl Med (2004); or Macchia I, et al. BioMed Research International (2013), each of which are incorporated herein by reference in their entireties.
Interleukin-2 (IL-2) is an interleukin, a type of cytokine signaling molecule in the immune system. IL-2 regulates the activities of white blood cells (for example, leukocytes and lymphocytes) that are responsible for immunity. IL-2 is part of the body's natural response to microbial infection, and in discriminating between foreign “non-self” and “self”. It mediates its effects by binding to IL-2 receptors, which are expressed by lymphocytes. Sequences for IL-2, also known TCGF and lympokine, are known for a number of species, e.g., human IL-2 (NCBI Gene ID: 3558) polypeptide (e.g., NCBI Ref Seq NP_000577.2) and mRNA (e.g., NCBI Ref Seq NM_000586.3). IL-2 can refer to human IL-2, including naturally occurring variants, molecules, and alleles thereof. IL-2 refers to the mammalian IL-2 of, e.g., mouse, rat, rabbit, dog, cat, cow, horse, pig, and the like. The nucleic sequence of SEQ ID NO: 5 comprises the nucleic sequence which encodes IL-2.
SEQ ID NO: 5 is the nucleotide sequence encoding IL-2.
Interleukin-12 (IL-12) is an interleukin naturally produced by dendritic cells, macrophages, neutrophils, and human B-lymphoblastoid cells (NC-37) in response to antigenic stimulation. IL-12 is involved in the differentiation of naive T cells into Th1 cells. It is known as a T cell-stimulating factor, which can stimulate the growth and function of T cells. It stimulates the production of interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) from T cells and natural killer (NK) cells, and reduces IL-4 mediated suppression of IFN-γ. Sequences for IL-12a, also known P35, CLMF, NFSK, and KSF1, are known for a number of species, e.g., human IL-12a (NCBI Gene ID: 3592) polypeptide (e.g., NCBI Ref Seq NP_000873.2) and mRNA (e.g., NCBI Ref Seq NM_000882.3). IL-12 can refer to human IL-12, including naturally occurring variants, molecules, and alleles thereof. IL-12 refers to the mammalian IL-12 of, e.g., mouse, rat, rabbit, dog, cat, cow, horse, pig, and the like. The nucleic sequence of SEQ ID NO:6 comprises the nucleic sequence which encodes IL-12a.
SEQ ID NO: 6 is the nucleotide sequence encoding IL-12a.
Interleukin-15 (IL-15) is an interleukin secreted by mononuclear phagocytes (and some other cells) following infection by virus(es). This cytokine induces cell proliferation of natural killer cells; cells of the innate immune system whose principal role is to kill virally infected cells. Sequences for IL-15 are known for a number of species, e.g., human IL-15 (NCBI Gene ID: 3600) polypeptide (e.g., NCBI Ref Seq NP_000585.4) and mRNA (e.g., NCBI Ref Seq NM_000576.1). IL-15 can refer to human IL-15, including naturally occurring variants, molecules, and alleles thereof. IL-15 refers to the mammalian IL-15 of, e.g., mouse, rat, rabbit, dog, cat, cow, horse, pig, and the like. The nucleic sequence of SEQ ID NO: 7 comprises the nucleic sequence which encodes IL-15.
SEQ ID NO: 7 is the nucleotide sequence encoding IL-15.
Antibodies or antibody reagents that bind to PD-1, or its ligand PD-L1, are described in U.S. Pat. Nos. 7,488,802; 7,943,743; 8,008,449; 8,168,757; 8,217,149, and PCT Published Patent Application Nos: WO03042402, WO2008156712, WO2010089411, WO2010036959, WO2011066342, WO2011159877, WO2011082400, and WO2011161699; which are incorporated by reference herein in their entireties. In certain embodiments the PD-1 antibodies include nivolumab (MDX 1106, BMS 936558, ONO 4538), a fully human IgG4 antibody that binds to and blocks the activation of PD-1 by its ligands PD-L1 and PD-L2; lambrolizumab (MK-3475 or SCH 900475), a humanized monoclonal IgG4 antibody against PD-1; CT-011 a humanized antibody that binds PD-1; AMP-224, a fusion protein of B7-DC; an antibody Fc portion; BMS-936559 (MDX-1105-01) for PD-L1 (B7-H1) blockade. Also specifically contemplated herein are agents that disrupt or block the interaction between PD-1 and PD-L1, such as a high affinity PD-L1 antagonist.
Non-limiting examples of PD-1 antibodies include: pembrolizumab (Merck); nivolumab (Bristol Meyers Squibb); pidilizumab (Medivation); and AUNP12 (Aurigene). Non-limiting examples of PD-L1 antibodies can include atezolizumab (Genentech); MPDL3280A (Roche); MEDI4736 (AstraZeneca); MSB0010718C (EMD Serono); avelumab (Merck); and durvalumab (Medimmune).
Antibodies that bind to OX40 (also known as CD134), are described in US patent Nos. U.S. Pat. Nos. 9,006,399, 9,738,723, 9,975,957, 9,969,810, 9,828,432; PCT Published Patent Application Nos: WO2015153513, WO2014148895, WO2017021791, WO2018002339; and US application Nos: US20180273632; US20180237534; US20180230227; US20120269825; which are incorporated by reference herein in their entireties.
Antibodies that bind to CTLA-4, are described in US patent Nos. U.S. Pat. Nos. 9,714,290, 6,984,720, 7,605,238, 6,682,736 U.S. Pat. No. 7,452,535; PCT Published Patent Application No: WO2009100140; and US application Nos: US20090117132A, US20030086930, US20050226875, US20090238820; which are incorporated by reference herein in their entireties.
Non-limiting examples of CTLA-4 antibodies include: ipilimumab (Bristol-Myers Squibb)
Antibodies that bind to TIM3, are described in US patent Nos. U.S. Pat. Nos. 8,552,156, 9,605,070, 9,163,087, 8,329,660; PCT Published Patent Application No: WO2018036561, WO2017031242, WO2017178493; and US application Nos: US20170306016, US20150110792, US20180057591, US20160200815; which are incorporated by reference herein in their entireties.
Antibodies that bind to TIGIT (also known as CD134), are described in US patent Nos. U.S. Ser. No. 10/017,572, U.S. Pat. No. 9,713,641; PCT Published Patent Application No: WO2017030823; and US application Nos: US20160355589, US20160176963, US20150322119; which are incorporated by reference herein in their entireties.
One aspect of the invention described herein provides a composition comprising any of the oncolytic HSV described herein. In one embodiment, the composition is a pharmaceutical composition. As used herein, the term “pharmaceutical composition” refers to the active agent in combination with a pharmaceutically acceptable carrier e.g. a carrier commonly used in the pharmaceutical industry.
In one embodiment, the composition further comprises at least one pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are well known in the art and include aqueous solutions such as physiologically buffered saline or other solvents or vehicles such as glycols, glycerol, vegetable oils (e.g., olive oil) or injectable organic esters. A pharmaceutically acceptable carrier can be used to administer the compositions of the invention to a cell in vitro or to a subject in vivo. A pharmaceutically acceptable carrier can contain a physiologically acceptable compound that acts, for example, to stabilize the composition or to increase the absorption of the agent. A physiologically acceptable compound can include, for example, carbohydrates, such as glucose, sucrose or dextrans, antioxidants, such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins or other stabilizers or excipients.
Other physiologically acceptable compounds include wetting agents, emulsifying agents, dispersing agents or preservatives, which are particularly useful for preventing the growth or action of microorganisms. Various preservatives are well known and include, for example, phenol and ascorbic acid. One skilled in the art would know that the choice of a pharmaceutically acceptable carrier, including a physiologically acceptable compound, depends, for example, on the route of administration of the oncolytic HSV.
The oncolytic viruses described herein or composition thereof can be administered to a subject having cancer. In one embodiment, an agent that regulates the tet operator is further administered with the oncolytic viruses described herein or composition thereof. Exemplary agents include, but are not limited to, doxycycline or tetracycline.
In one embodiment, the cancer is a solid tumor. The solid tumor can be malignant or benign. In one embodiment, the subject is diagnosed or has been diagnosed with having a carcinoma, a melanoma, a sarcoma, a germ cell tumor, and a blastoma. Exemplary cancers include, but are in no way limited to, non-small-cell lung cancer, breast cancer, brain cancer, colon cancer, prostate cancer, liver cancer, lung cancer, ovarian cancer, skin cancer, and pancreatic cancer. In one embodiment, the cancer is metastatic. These types of cancers are known in the art and can be diagnosed by a skilled clinician using standard techniques known in the art, for example blood analysis, blood cell count analysis, tissue biopsy non-invasive imaging, and review of family history.
In cases where tumors are readily accessible, e.g., tumors of the skin, mouth or which are accessible as the result of surgery, virus can be applied topically. In other cases, it can be administered by injection or infusion. The agent that regulates the tet operator, for example doxycycline or tetracycline, used prior to infection or at a time of infection can also be administered in this way or it can be administered systemically.
Although certain routes of administration are provided in the foregoing description, according to the invention, any suitable route of administration of the vectors may be adapted, and therefore the routes of administration described above are not intended to be limiting. Routes of administration may including but are not limited to, intravenous, oral, buccal, intranasal, inhalation, topical application to a mucosal membrane or injection, including intratumoral, intradermal, intrathecal, intracisternal, intralesional or any other type of injection. Administration can be effected continuously or intermittently and will vary with the subject and the condition to be treated. One of skill in the art would readily appreciate that the various routes of administration described herein would allow for the inventive vectors or compositions to be delivered on, in, or near the tumor or targeted cancer cells. One of skill in the art would also readily appreciate that various routes of administration described herein will allow for the vectors and compositions described herein to be delivered to a region in the vicinity of the tumor or individual cells to be treated. “In the vicinity” can include any tissue or bodily fluid in the subject that is in sufficiently close proximity to the tumor or individual cancer cells such that at least a portion of the vectors or compositions administered to the subject reach their intended targets and exert their therapeutic effects.
Prior to administration, the oncolytic viruses can be suspended in any pharmaceutically acceptable solution including sterile isotonic saline, water, phosphate buffered saline, 1,2-propylene glycol, polyglycols mixed with water, Ringer's solution, etc. The exact number of viruses to be administered is not crucial to the invention but should be an “effective amount,” i.e., an amount sufficient to cause cell lysis extensive enough to generate an immune response to released tumor antigens. Since virus is replicated in the cells after infection, the number initially administered will increase rapidly with time. Thus, widely different amounts of initially administered virus can give the same result by varying the time that they are allowed to replicate, i.e., the time during which cells are exposed to tetracycline. In general, it is expected that the number of viruses (PFU) initially administered will be between 1×106 and 1×1010.
Tetracycline or doxycycline will be administered either locally or systemically to induce viral replication at a time of infection or 1-72 h prior to infection. The amount of tetracycline or doxycycline to be administered will depend upon the route of delivery. In vitro, 1 μg/ml of tetracycline is more than sufficient to allow viral replication in infected cells. Thus, when delivered locally, a solution containing anywhere from 0.01 μg/ml to 100 μg/ml may be administered. However, much higher doses of tetracycline or doxycycline (e.g., 10-500 mg/ml) can be employed if desired. The total amount given locally at a single time will depend on the size of the tumor or tumors undergoing treatment but in general, it is expected that between 0.5 and 200 ml of tetracycline solution would be used at a time. When given systemically, higher doses of tetracycline will be given but it is expected that the total amount needed will be significantly less than that typically used to treat bacterial infections (usually 1-2 grams per day in adults divided into 2-4 equal doses and, in children, 10-20 mg per pound of body weight per day). It is expected that 100-200 mg per day should be effective in most cases.
The effectiveness of a dosage, as well as the effectiveness of the overall treatment can be assessed by monitoring tumor size using standard imaging techniques over a period of days, weeks and/or months. A shrinkage in the size or number of tumors is an indication that the treatment has been successful. If this does not occur or continue, then the treatment can be repeated as many times as desired. In addition, treatment with virus can be combined with any other therapy typically used for solid tumors, including surgery, radiation therapy or chemotherapy. In addition, the procedure can be combined with methods or compositions designed to help induce an immune response.
As used herein, the term “therapeutically effective amount” is intended to mean the amount of vector which exerts oncolytic activity, causing attenuation or inhibition of tumor cell proliferation, leading to tumor regression. An effective amount will vary, depending upon the pathology or condition to be treated, by the patient and his or her status, and other factors well known to those of skill in the art. Effective amounts are easily determined by those of skill in the art. In some embodiments a therapeutic range is from 103 to 1012 plaque forming units introduced once. In some embodiments a therapeutic dose in the aforementioned therapeutic range is administered at an interval from every day to every month via the intratumoral, intrathecal, convection-enhanced, intravenous or intra-arterial route.
The invention provided herein can further be described in the following numbered paragraphs:
HSV replicates in epithelial cells and fibroblasts and establishes life-long latent infection in neuronal cell bodies within the sensory ganglia of infected individuals. During productive infection, HSV genes fall into three major classes based on the temporal order of their expression: immediate-early (IE), early (E), and late (L) (Roizman, 2001). The HSV-1 viral proteins directly relevant to the current study are two IE regulatory proteins, ICP27 and ICP0. ICP27 is an essential viral IE protein that modifies and transports viral transcripts to the cytoplasm (Sandri-Goldin, 2008). Although not essential for productive infection, ICP0 is required for efficient viral gene expression and replication at low multiplicities of infection in normal cells and efficient reactivation from latent infection (Cai and Schaffer, 1989; Leib et al., 1989; Yao and Schaffer, 1995). Studies have revealed that ICP0 is needed to stimulate translation of viral mRNA in quiescent cells (Walsh and Mohr, 2004) and plays a key role in blocking IFN-induced inhibition of viral infection (Eidson et al., 2002; Mossman et al., 2000). ICP0 also has E3 ubiquitin ligase activity and induces the disruption and degradation of ND10 proteins that have been implicated in controlling cell senescence and DNA repair (Everett, 2006). Given that tumor cells are impaired in various cellular pathways, such as DNA repair, interferon signaling, and translation regulation (Kastan and Bartek, 2004; Mohr, 2005), it is not surprising that ICP0 deletion mutants replicate more efficiently in cancer cells than in normal cells, in particular, quiescent cells and terminally differentiated cells. The oncolytic potential of ICP0 mutants was first illustrated by Yao and Schaffer (Yao and Schaffer, 1995), who showed that the plaque-forming efficiency of an ICP0 null mutant in human osteosarcoma cells (U2OS) is 100- to 200-fold higher than in non tumorigenic African green monkey kidney cells (Vero). The preferential ability of ICP0 mutants to replicate in selected types of cancer cells has been further explored in the recent study of Hummel et al. with an HSV-1 virus lacking both ICP0 and HSV-1 virion-associated transactivator, VP16 (Hummel et al., 2005).
Using the T-REx™ (Invitrogen, CA) gene switch technology and a self-cleaving ribozyme, a novel regulatable oncolytic HSV-1 recombinant, KTR27, which encodes the tetR gene controlled by the ICP0 promoter at the ICP0 locus and the essential ICP27 gene under control of the tetO-bearing ICP27 promoter was constructed (Yao et al., 2010). Infection of normal replicating cells as well as multiple human cancer cell types with KTR27 in the presence of tetracycline led to 1000- to 250,000-fold higher progeny virus production than in the absence of tetracycline, while little viral replication and virus-associated cytotoxicity are observed in infected growth-arrested normal human cells. Intratumoral inoculation with KTR27 was shown to markedly inhibit tumor growth in a xenograft model of human non-small-cell lung cancer in nude mice. It was shown further that replication of KTR27 in the inoculated tumors can be efficiently controlled by local co-delivery of tetracycline to the target tumors at the time of KTR27 inoculation. Collectively, KTR27 possesses a unique pharmacological feature that can limit its replication to the targeted tumor microenvironment with localized tetracycline delivery, thus minimizing unwanted viral replication in distant tissues following local virotherapy. This regulatory mechanism would also allow the replication of the virus to be quickly shut down should adverse effects be detected.
Human cancers are heterogeneous and contain multiple barriers that limit viruses from efficiently infecting distant tumor cells following initial viral replication (McKee et al., 2006; Nagano et al., 2008; Pluen et al., 2001). In an effort to overcome the inability of oncolytic viruses or viral vectors to infect or deliver therapeutic gene to large number of tumor cells within the tumor mass, a viral fusogenic glycoprotein approach has been employed. It was specifically contemplated that a fusogenic variant of KTR27 could offer a significant immunological benefit in augmenting the anti-tumor response induced by KTR27.
HSV encodes several surface glycoproteins that involve the fusion of the viral envelope with the cell membrane as well as the fusion of an infected cell with adjacent cells, leading to syncytia. HSV variants exhibiting extensive syncytium formation consisting of as many as thousands of nuclei can be isolated by the propagation of virus in cell cultures (Pertel and Spear, 1996). Studies have shown that mutations in the cytoplasmic domain of HSV-1 glycoprotein B (gB) can lead to extensive syncytial (Baghian A et al., J Virol. 67:2396-2401, 1993; Bzik D J et al., Virology 137:185-190, 1984; Cai W H et al., J Virol 62:2596-2604, 1988; Engel J P et al., Virology 192:112-120, 1993; Diakidi-Kosta A et al., Gage P J et al., J Virol 67:2191-2201, 1993; Virus Res 93-99-108, 2003). HSV-1 syncytial mutations have also been identified in gene encoding for glycoprotein K (gK) (Bond V C et al., J Gen Virol 61:245-254, 1982; Bond V C and Person S, Virology 132:368-376, 1984; Debroy C et al., et al., Virology 145:36-48, 1985; Hutchinson et al., J Virol 66:5603-5609; Pogue-Geile K L et al., Virology 136:100-109, 1984; Pogue-Geile K L et al., Virology 157:67-74, 1987), the UL20 gene (Melancon J M et al., J Virol 78:7329-7343, 2004) and the UL24 gene (Sanders P G et al., J Gen Virol 63:277-95, 1982; Jacobson J G et al., J Virol 63:1839-1843; Jacobson J G et al., Virology 242:161-169, 1998). Notably, UL20 interacts with both gB and gK (Foster T P et al., J Virol 82:6310-6323, 2008; Chouljenko V N et al., J Virol 84:8596-8606).
During the propagation of KTR27 in U2OS cells, the presence of fusogenic forms of KTR27 was noticed in addition to the non-fusogenic regular KTR27 in passage 3 KTR27 stock. KTR27-F was a second-round plaque-purified syncytium-forming KTR27 variant (KTR27-F) with a plaque size ˜12 times larger than that of parental KTR27 and exhibited similar replication efficiency as KTR27 in U2OS cells. While the replication efficiency of KTR27-F and KTR27 is comparable in the tested various human cancer cell lines, it was shown that KTR27-F exhibits more stringent tet-dependent regulation in these cells lines with regulatability ranges from ˜65,000-fold to ˜881,000-fold, whereas the degrees of KTR27 regulation ranged from ˜785-fold to ˜37,000-fold. The effectiveness of KTR27-F in killing tested human lung and breast tumor cell lines is enhanced 11 to 37-fold at a low multiplicity of infection.
Sequence analyses of KTR27-F genome confirms that KTR27-F encodes tetR at the HSV-1 ICP0 locus, and ICP27 under the control of the tetO-containing ICP27 promoter with a self-cleaving ribozyme present at the 5′ untranslated region of ICP27 gene. Using the parental wild-type HSV-1 strain KOS genome as the reference, a single amino acid substitution, Ala to Val at residue 40, is identified in the gK gene of KTR27-F, while no mutation is found in the gB gene and the UL20 gene. KTR27-F also contains a single amino acid substitution, Ser to Asn at the residue 113 in UL24 gene. Because the same Ala to Val substitution has been identified in the HSV-1 syncytial mutants, syn102, syn105 and syn 33 (Dolter K E et al., J Virol 68:8277-8281, 1994), which were isolated from KOS-infected cells in the presence of mutagens, 2-aminopurine (Bond V C et al., J Gen Virol 61:245-254, 1982) or 5-bromodeoxyuridine (Read G S et al., J Virol 35:105-113, 1980), it is specifically contemplated that the Ala to Val substitution at residue 40 of the gK gene in KTR27-F is a key factor for the observed fusogenic phenotype. Previous studies identified several additional syncytial mutations in the gK gene, which include Ala to Thr at residue 40 in syn20, Asp to Asn at residue 99 in syn31 and syn32, Leu to Pro at residue 304 in syn30, and Arg to Leu at residue 310 (Dolter K E et al., J Virol 68:8277-8281, 1994). Whether the Ser to Asn substitution at residue 113 in the UL24 gene contributes to the fusogenic activity of KTR27-F remains to be determined.
Surprisingly, sequencing analysis indicates that KTR27-F does not encode the HSV-1 ICP34.5 gene. Like ICP0, the ICP34.5 gene is located in the inverted repeat region that flanks the unique long region of the HSV-1 genome. PCR analyses with primers specific for the ICP34.5 gene indicate that the ICP34.5 gene is likely non-specifically lost during the construction of K0R27-lacZ, the parental virus of KTR27.
Materials and Methods
Cells and Viruses
The osteosarcoma line U2OS and the African green monkey kidney cell line (Vero) were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Yao and Schaffer, 1995). U2OS cells express a cellular activity that can effectively complement the function of the HSV-1 IE regulatory protein ICP0 lacking in ICP0-mutant viruses (Yao and Schaffer, 1995). Primary human fibroblasts were grown in DMEM containing 10% FBS plus 1×non-essential amino acids (Yao and Eriksson, 1999).
Human non-small-cell lung cancer cells (H1299), human breast cancer cells (MCF7), human prostate cancer cells (PC1435), and pancreatic cancer cells (Panc 1) were cultured in DMEM containing 10% FBS. PC1435 and MCF7 were kindly provided by Dr. Sheng Xiao (Brigham and Women's Hospital). Panc 1 was the kind gift of Dr. Edward Hwang (Brigham and Women's Hospital).
7134 is an ICP0-null mutant derived from HSV-1 strain KOS, in which both copies of the ICP0 coding sequence are replaced by the LacZ gene of Escherichia coli (Cai and Schaffer, 1989). 7134 was propagated and assayed in U2OS cells (Yao and Schaffer, 1995). K0R is an HSV-1 recombinant generated by recombinational replacement of the LacZ gene in 7134 with the DNA sequence encoding tetR (Yao et al., 2006). K0R27-lacZ was derived from K0R in which the ICP27 coding sequence was replaced with the LacZ gene by homologous recombination (Yao et al., 2010). KTR27 is a 7134-derived recombinant virus that encodes tetR under the control of HSV-1 ICP0 promoter at the ICP0 locus, and the essential ICP27 gene under the control of the tetO-containing ICP27 promoter and a self-cleaving ribozyme located at the 5′ untranslated region of ICP27 coding sequence (Yao et al., J Virol, 2010) (U.S. Pat. No. 8,236,941).
Neurovirulence of KTR27-F
A mouse model for the evaluation of the neurovirulence of KTR27-F was established by injecting 4-6 week female CD1 outbred mice (Charles River Laboratories, Wilmington, Mass.) with 20 μl of medium containing 1×107 PFU of KTR27-F or 7134. Intracerebral inoculation was performed with a 28½ gauge needle with a needle guard such that the distance from the guard to the needle tip was 5.5 mm, and to the beginning of the bevel of the needle was 4.5 mm. The needle was inserted at a point equidistant between the outer canthus of the eye, the front of the pinna, and midline of the head (Lynas et al., 1993). Half of the mice inoculated with KTR27-F were given a normal diet, and the other half were fed a doxycycline-containing diet at 200 mg/kg (Bio-Serv, Frenchtown, N.J.), beginning 3 days prior to inoculation and lasting for the duration of the experiment. Mice were examined for signs of illness for 29 days following inoculation.
All mouse studies were conducted in accordance with the protocols set forth by the Harvard Medical Area Standing Committee on Animals and the American Veterinary Medical Association. The Harvard Medical School animal management program is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) and meets National Institutes of Health standards as set forth in “The Guide for the Care and Use of Laboratory Animals” (National Academy Press, 1996).
Illumina Sequencing
KTR27-F viral DNA was prepared from KTR27-F-infected U2OS cells with Qiagen Genomic DNA kit. Quantitative real-time PCR analysis reveals close to 55% of total DNA represents KTR27F viral DNA. The isolated DNA (2.2 μg) was used for library construction with TruSeq DNA OCR-Free Library Preparation Kits at Translational Genomics Core Facility, Partners HealthCare, Cambrige, Mass., targeting 550 bp fragments, and were sequenced on a 250 bp MiSeq run. The resulting contigs were assembled and analyzed in Illumina MiSeq Reporter Resequencing workflow using HSV-1 strain KOS genome as the reference.
Results
Selection of KTR27-F. During the propagation of KTR27 in U2OS cells, the presence of fusogenic forms of KTR27 was noticed in addition to the non-fusogenic regular KTR27 in passage 3 KTR27 stock. To isolate fusogenic variants of KTR27, passage 3 KTR27 was diluted with DMEM containing 10% FBS followed by plaque purification. Specifically, 10×100 mm dishes of confluent 72 h-old U2OS cells were infected with the diluted passage 3 KTR27 at either 100 PFU/dish or 200 PFU/dish. After 1 h incubation at 37 C, inoculation medium was removed and 10 ml/dish of DMEM growth medium containing tetracycline at 10 μg/ml were added to each dish. After an additional 3 h incubation at 37 C, tetracycline-containing medium was removed from individual dishes followed by addition of 1 ml/dish of fresh tetracycline-containing DMEM growth medium, Infected cells were then overlaid with 1% methylcellulose prepared in DMEM containing 5% FBS at 25 ml/dish. After incubation at 37 C for 72 h, infected dishes were stained with 10 ml/dish of 0.02% neutral-red prepared in DMEM. Individual single fusogenic plaques were picked at 20 h post neutral-red staining and suspended in 1.5 ml of DMEM growth medium followed by amplification in U2OS cells in the presence of tetracycline. KTR27-F was a second-round plaque-purified syncytium-forming KTR27 variant with a plaque size ˜12-13 times larger than that of parental KTR27 at 48 and 72 h post-infection (
Control of KTR27-F replication by tetracycline. To assess the dependence of KTR27-F replication on the presence of tetracycline, Vero cells were infected with KTR27-F at a MOI of 1 PFU/cell in the presence and absence of tetracycline and the infected cells were harvested at 48 and 72 h post-infection (
Tetracycline-dependent replication of KTR27-F in cultured human tumor cells and primary cells. Having demonstrated that the replication of KTR27-F is as productive as that of KTR27 in Vero cells, and that KTR27-F is unable to replicate in Vero cells in the absence of tetracycline, the replicative and regulative abilities of KTR27-F in various human tumor cell lines were then investigated. As a control, KTR27 was also used in these experiments. As depicted in
The drastic enhancement of the cytotoxic effect of KTR27-F relative to that of KTR27 is best visualized by the cytotoxicity assays depicted in
Neurovirulence of KTR27-F. The ability of an oncolytic viral recombinant to replicate efficiently in tumor cells must be balanced against the potentially dangerous side effects of its replication in non-tumor tissues. HSV is highly neurotropic, and thus a clinically-relevant HSV recombinant ideally causes little to no neurovirulence. KTR27 was previously demonstrated to be avirulent following intracerebral inoculation in mice (Yao et al., 2010), herein, a similar assay was conducted with KTR27-F to investigate should the enhanced cytotoxicity of KTR27-F in the presence of tetracycline in cancer cells lead to a higher degree of neurovirulence. In brief, mice receiving a doxycycline-containing diet or normal diet were intracerebrally inoculated with KTR27-F at a dose of 1×107 PFU/mouse (
Sequence analyses of KTR27-F genome. As expected, sequence analysis of KTR27-F viral genome confirms that KTR27-F encodes tetR at the HSV-1 ICP0 locus, and ICP27 under the control of the tetO-containing ICP27 promoter with a self-cleaving ribozyme present at the 5′ untranslated region of ICP27 gene. Using the parental wild-type HSV-1 strain KOS genome as the reference, a total of 58 missense mutations and 2 frame shift mutations are identified in the KTR27-F genome. The UL36 gene of KTR27-F contains 16 missense mutations and 2 frame shift mutations. Other missense mutations are located in the UL5 gene, the UL8 gene, the UL12 gene, the UL13 gene, the UL16 gene, UL17 gene, UL19 gene, the UL24 gene, the UL25 gene, UL26 gene, the UL28 gene, the UL29 gene, the UL30 gene, the UL37 gene, the UL39 gene, the UL40 gene, the UL44 gene, UL47 gene, the UL52 gene, the UL53 gene (gK), the US1 gene, and the US8 gene.
A single amino acid substitution, Ala to Val at residue 40, is identified in the gK gene of KTR27-F. The same Ala to Val substitution has been identified in the HSV-1 syncytial mutants, syn102, syn105 and syn 33 (Dolter K E et al., J Virol 68:8277-8281, 1994), which were isolated from KOS-infected cells in the presence of mutagens, 2-aminopurine (Bond V C et al., J Gen Virol 61:245-254, 1982) or 5-bromodeoxyuridine (Read G S et al., J Virol 35:105-113, 1980), indicating that the Ala to Val substitution at residue 40 of the gK gene in KTR27-F is a key factor for the observed fusogenic phenotype. Syncytial mutations in the gK gene also include Ala to Thr at residue 40 in syn20, Asp to Asn at residue 99 in syn31 and syn32, Leu to Pro at residue 304 in syn30, and Arg to Leu at residue 310 (Dolter K E et al., J Virol 68:8277-8281, 1994). In addition to the single amino acid substitution in the gK gene, KTR27-F contains a single amino acid substitution of Ser to Asn in UL24 gene at residue 113. Whether this Ser to Asn substitution contributes to the fusogenic activity of KTR27-F remains to be determined. No mutation is found in the gene encoding gB and the UL20 gene.
Unexpectedly, sequencing analysis of KTR27-F reveals that the HSV-1 ICP34.5 gene is missing from the KTR27-F genome. To date, most of HSV-1 based oncolytic viruses are based on deletion of the ICP34.5 gene or through conditional regulations of ICP34.5 expression (Aghi M and Martuza R L, Oncogen 24:7802-7816, 2005; Lawler S E et al., JAMA Oncology, 2016). The ICP35.5 deletion mutant-based HSV-1 oncolytic virus, T-Vec (Amgen) has been approved for the treatment of advanced-stage melanoma in late 2015. Like ICP0, the ICP34.5 gene is located in the inverted repeat region that flanks the unique long region of the HSV-1 genome. PCR analyses with primers specific for the ICP34.5 gene indicate that while both 7134 and K0R yield a predicated ICP34.5-specific amplified PCR fragment, no ICP34.5-specific DNA fragment was detected in PCR reactions with KTR27, KTR27-F, and K0R27-lacZ viral DNA. PCR analysis with tetR-specific primers confirm that KTR27, KTR27-F, and K0R27-lacZ encode tetR at the ICP0 locus. Collectively, these results indicate that the ICP34.5 gene was likely lost during the construction of K0R27-lacZ virus.
The various methods and techniques described above provide a number of ways to carry out the application. Of course, it is to be understood that not necessarily all objectives or advantages described can be achieved in accordance with any particular embodiment described herein. Thus, for example, those skilled in the art will recognize that the methods can be performed in a manner that achieves or optimizes one advantage or group of advantages as taught herein without necessarily achieving other objectives or advantages as taught or suggested herein. A variety of alternatives are mentioned herein. It is to be understood that some preferred embodiments specifically include one, another, or several features, while others specifically exclude one, another, or several features, while still others mitigate a particular feature by inclusion of one, another, or several advantageous features.
Furthermore, the skilled artisan will recognize the applicability of various features from different embodiments. Similarly, the various elements, features and steps discussed above, as well as other known equivalents for each such element, feature or step, can be employed in various combinations by one of ordinary skill in this art to perform methods in accordance with the principles described herein. Among the various elements, features, and steps some will be specifically included and others specifically excluded in diverse embodiments.
Although the application has been disclosed in the context of certain embodiments and examples, it will be understood by those skilled in the art that the embodiments of the application extend beyond the specifically disclosed embodiments to other alternative embodiments and/or uses and modifications and equivalents thereof.
In some embodiments, the terms “a” and “an” and “the” and similar references used in the context of describing a particular embodiment of the application (especially in the context of certain of the following claims) can be construed to cover both the singular and the plural. The recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (for example, “such as”) provided with respect to certain embodiments herein is intended merely to better illuminate the application and does not pose a limitation on the scope of the application otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the application.
Other than in the operating examples, or where otherwise indicated, all numbers expressing quantities of ingredients or reaction conditions used herein should be understood as modified in all instances by the term “about.” The term “about” when used in connection with percentages can mean±1%.
Preferred embodiments of this application are described herein, including the best mode known to the inventors for carrying out the application. Variations on those preferred embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. It is contemplated that skilled artisans can employ such variations as appropriate, and the application can be practiced otherwise than specifically described herein. Accordingly, many embodiments of this application include all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the application unless otherwise indicated herein or otherwise clearly contradicted by context.
All patents, patent applications, publications of patent applications, and other material, such as articles, books, specifications, publications, documents, things, and/or the like, referenced herein are hereby incorporated herein by this reference in their entirety for all purposes, excepting any prosecution file history associated with same, any of same that is inconsistent with or in conflict with the present document, or any of same that may have a limiting affect as to the broadest scope of the claims now or later associated with the present document. By way of example, should there be any inconsistency or conflict between the description, definition, and/or the use of a term associated with any of the incorporated material and that associated with the present document, the description, definition, and/or the use of the term in the present document shall prevail.
This application claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 62/769,280 filed Nov. 19, 2018, the contents of which is incorporated herein by reference in its entirety.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2019/061662 | 11/15/2019 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 62769280 | Nov 2018 | US |
